HC Surgical Specialists Limited (SGX:1B1) Acquires Majority Stake in NYK Endoscopy and Digestive Centre Pte. Ltd.
Key Highlights
- Acquisition of 51% stake in NYK Endoscopy and Digestive Centre Pte. Ltd. (“NYKPL”) for S\$750,000, completed on 8 June 2026.
- Dr. Ng Yi Kang, a highly experienced gastroenterologist and hepatologist, joins as manager of NYKPL for a minimum of 11 years.
- NYKPL to provide endoscopic procedures, synergizing with HCSS’s core business and expanding its service offerings.
- Potential full acquisition: HCSS plans to acquire the remaining 49% stake at a later stage, indicating further consolidation.
Detailed Overview
On 8 June 2026, HC Surgical Specialists Limited (“HCSS”), a leading Catalist-listed medical services group in Singapore, announced the acquisition of a 51% equity interest in NYK Endoscopy and Digestive Centre Pte. Ltd. (“NYKPL”) for a total consideration of S\$750,000. This purchase was concluded through a sale and purchase agreement with Dr. Ng Yi Kang, who will retain a 49% stake and serve as the managing specialist physician for at least 11 years starting from around 1 July 2026.
NYKPL, incorporated on 2 June 2026, is a newly established medical entity that has yet to commence operations. Its principal activity will focus on providing endoscopic procedures, including advanced gastrointestinal physiology testing. This aligns with HCSS’s existing strengths in general surgery and endoscopy, and is expected to generate significant operational synergies across HCSS’s network of 19 clinics in Singapore.
Significance of Dr. Ng Yi Kang’s Appointment
Dr. Ng is a seasoned gastroenterologist and hepatologist with over 15 years of experience in public healthcare, most recently serving as a Consultant Gastroenterologist and Hepatologist and clinical lead at Sengkang General Hospital. His expertise covers disorders of gut-brain interaction, GERD, advanced endoscopic diagnostics and therapeutics, and GI motility testing. Dr. Ng’s appointment is expected to enhance HCSS’s clinical leadership and bolster its capacity to address Singapore’s growing demand for digestive health services.
Notably, Dr. Ng has committed to managing NYKPL for at least 11 years, ensuring continuity and stability in the new venture.
Financial and Strategic Implications
- The S\$750,000 purchase consideration for the 51% stake will be funded through internal resources or bank borrowings, reflecting HCSS’s prudent capital management strategy.
- HCSS retains the option to acquire the remaining 49% of NYKPL in the future, signaling intentions for full ownership and integration.
- This transaction is part of HCSS’s broader expansion into endoscopy services, in response to Singapore’s aging demographic and rising demand for gastroenterological care.
Potential Share Price Impact / Price-Sensitive Information
- Expansion of Service Capabilities: The acquisition and Dr. Ng’s involvement significantly strengthen HCSS’s capabilities in digestive health and advanced endoscopy, potentially boosting future revenue streams and market share.
- Growth Pipeline: The announcement of plans to acquire the remaining 49% indicates a possible future capital outlay and further consolidation, which may affect long-term investor expectations.
- Experienced Leadership: Dr. Ng’s long-term commitment and track record in public healthcare add credibility and stability to the venture, likely to be viewed positively by investors seeking sustainable growth.
About HC Surgical Specialists Limited
HCSS was incorporated in 2015 and listed on the Catalist of the Singapore Exchange in 2016. It operates a network of 19 clinics across Singapore, specializing in endoscopic procedures (gastroscopies, colonoscopies) and general surgery with a focus on colorectal treatments.
For more information, visit hcsurgicalspecialists.com.
Investor Relations Contact
Email: [email protected]
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult professional advisors before making any investment decisions. The Singapore Exchange and Novus Corporate Finance Pte. Ltd. have not reviewed or endorsed the contents of this article.
HC Surgical Specialists Limited（SGX:1B1）收购 NYK 内窥镜与消化中心多数股权
要点摘要
- 以 75 万新元收购 NYK 内窥镜与消化中心 Pte. Ltd.（NYKPL）51% 股权，交易于 2026 年 6 月 8 日完成。
- 资深肠胃及肝病专家 Dr. Ng Yi Kang 将至少管理 NYKPL 11 年，保障团队稳定和持续发展。
- NYKPL 主要提供内窥镜检查服务，与集团现有业务形成协同效应，拓展服务能力。
- 未来可能全面收购：HCSS 计划日后收购剩余 49% 股权，显示有意进一步整合。
详细内容
2026 年 6 月 8 日，HC Surgical Specialists Limited（HCSS）宣布以 75 万新元收购 NYK 内窥镜与消化中心 Pte. Ltd.（NYKPL）51% 股权。交易对象为 Dr. Ng Yi Kang，后者保留 49% 股权，并将自 2026 年 7 月起至少担任 NYKPL 的管理专家 11 年。
NYKPL 于 2026 年 6 月 2 日注册成立，目前尚未开展业务。公司主营内窥镜检查及消化系统相关测试，与 HCSS 现有的胃肠与外科业务高度协同，有助于提升集团在新加坡 19 家诊所网络的整体服务能力。
Dr. Ng Yi Kang 的重要作用
Dr. Ng 拥有超过 15 年公立医院临床经验，专长于肠脑互动障碍、胃食管反流病、内窥镜诊断与治疗及胃肠动力学检测，曾任升康综合医院顾问和相关临床负责人。他的加盟被视为提升 HCSS 医疗领导力和专业能力的重要举措，有助于应对新加坡人口老龄化带来的消化健康需求增长。
值得注意的是，Dr. Ng 已承诺至少管理 NYKPL 11 年，保障新业务的稳定运营。
财务及战略意义
- 本次 51% 股权的收购对价 75 万新元，将通过公司内部资源和/或银行贷款支付，显示公司资金管理审慎。
- HCSS 计划日后收购剩余 49% 股权，表明有意实现全面整合。
- 该交易是集团进一步拓展内窥镜业务的重要战略举措，顺应新加坡社会对消化健康服务日益增长的需求。
股价潜在影响 / 敏感信息
- 服务能力提升：此次收购及 Dr. Ng 加盟将大幅加强 HCSS 在消化健康及内窥镜领域的能力，有望带动未来营收和市场份额增长。
- 成长管线：未来全面收购 NYKPL 计划提供了进一步增长预期，可能对投资者信心和股价产生影响。
- 经验丰富的领导：Dr. Ng 的长期承诺和公立医疗背景为新业务带来信誉和稳定性，有望获得市场积极评价。
关于 HC Surgical Specialists Limited
HCSS 于 2015 年成立，2016 年在新加坡交易所 Catalist 板块上市，目前在全国拥有 19 家诊所，专注于内窥镜（胃镜、肠镜）及以结直肠手术为主的综合外科服务。
更多信息请访问 hcsurgicalspecialists.com。
投资者关系联系方式
免责声明
本文仅供参考，不构成投资建议。投资者应自行进行尽职调查，并咨询专业顾问后作出投资决定。新加坡交易所及 Novus Corporate Finance Pte. Ltd. 并未审阅或认可本内容。
